Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis.

Sherko Kummel; Pauline Wimberger; Gunter Von Minckwitz; Valentina Nekljudova; Carsten Denkert; Marianne Just; Claus Hanusch; Oliver J Stoetzer; Jens Bodo Huober; Manfred Hofmann; Christian Jackisch; Jens U. Blohmer; Valentina Vladimirova; Andreas Schneeweiss; Michael Untch; Sibylle Loibl

doi:10.1200/jco.2018.36.15_suppl.569

Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An iterim safety analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.569 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 569-569 ◽

Cited By ~ 2

Author(s):

Sherko Kummel ◽

Pauline Wimberger ◽

Gunter Von Minckwitz ◽

Valentina Nekljudova ◽

Carsten Denkert ◽

...

Keyword(s):

Breast Cancer ◽

Factorial Design ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Safety Analysis

Download Full-text

Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX)

10.1055/s-0038-1651752 ◽

2018 ◽

Author(s):

S Kümmel ◽

G Minckwitz ◽

V Vladimirova ◽

V Nekljudova ◽

P Wimberger ◽

...

Keyword(s):

Breast Cancer ◽

Factorial Design ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment

Download Full-text

Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps635 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS635-TPS635 ◽

Cited By ~ 3

Author(s):

Sherko Kümmel ◽

Gunter Von Minckwitz ◽

Valentina Nekljudova ◽

Serban Dan Costa ◽

Carsten Denkert ◽

...

Keyword(s):

Breast Cancer ◽

Factorial Design ◽

Hormone Receptor ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment

Download Full-text

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

PLoS ONE ◽

10.1371/journal.pone.0143643 ◽

2015 ◽

Vol 10 (12) ◽

pp. e0143643 ◽

Cited By ~ 12

Author(s):

Yoshie Hasegawa ◽

Hirokazu Tanino ◽

Jun Horiguchi ◽

Daishu Miura ◽

Takashi Ishikawa ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Zoledronic Acid ◽

Primary Breast Cancer ◽

Controlled Trial ◽

Neoadjuvant Treatment ◽

Randomized Controlled

Download Full-text

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Breast Cancer ◽

10.1007/s12282-018-0839-7 ◽

2018 ◽

Vol 25 (4) ◽

pp. 407-415 ◽

Cited By ~ 5

Author(s):

N. Masuda ◽

M. Toi ◽

N. Yamamoto ◽

H. Iwata ◽

K. Kuroi ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Therapy ◽

Primary Breast Cancer ◽

Prolonged Exposure ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase

Download Full-text

Dual Blockade with Afatinib and Trastuzumab As Neoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy (Dafne)-Gbg70 – Efficacy and Safety Analysis

Annals of Oncology ◽

10.1093/annonc/mdu327.3 ◽

2014 ◽

Vol 25 ◽

pp. iv86

Author(s):

C. Hanusch ◽

A. Schneeweiss ◽

M. Untch ◽

S. Paepke ◽

S. Kümmel ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Neoadjuvant Treatment ◽

Safety Analysis ◽

Operable Breast Cancer ◽

Efficacy And Safety ◽

Dual Blockade

Download Full-text

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.537 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 537-537 ◽

Cited By ~ 4

Author(s):

M. Dowsett ◽

I. E. Smith

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Molecular Effects ◽

The Impact

Download Full-text

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.537 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 537-537

Author(s):

M. Dowsett ◽

I. E. Smith

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment ◽

Molecular Effects ◽

The Impact

Download Full-text

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2007.07.002 ◽

2008 ◽

Vol 66 (1) ◽

pp. 31-41 ◽

Cited By ~ 28

Author(s):

George Lazaridis ◽

George Pentheroudakis ◽

Nicholas Pavlidis

Keyword(s):

Breast Cancer ◽

Primary Breast Cancer ◽

Neoadjuvant Treatment

Download Full-text

24 Zoledronic acid (ZOL) as add-on therapy in patients with tumour residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70055-0 ◽

2010 ◽

Vol 8 (3) ◽

pp. 65 ◽

Cited By ~ 1

Author(s):

G. von Minckwitz ◽

M.D. Zahm ◽

H. Eidtmann ◽

H. Tesch ◽

A. du Bois ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Neoadjuvant Chemotherapy ◽

Primary Breast Cancer ◽

Safety Analysis

Download Full-text

Geparquinto: First Planned Safety Analysis on 60 Patients with HER2 Negative Primary Breast Cancer Receiving Neoadjuvant Chemotherapy ± Bevacizumab or ± RAD001 (GBG 44).

10.1158/0008-5472.sabcs-09-1096 ◽

2009 ◽

Author(s):

G. von Minckwitz ◽

I. Bauerfeind ◽

B. Gerber ◽

J. Huober ◽

H. Eidtmann ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Primary Breast Cancer ◽

Safety Analysis

Download Full-text